News | January 28, 2026
Parse Biosciences unveils integrated immune profiling in Trailmaker Platform
The new functionality complements Parse’s existing Evercode immune products
The new functionality complements Parse’s existing Evercode immune products
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
VETMEDIN (pimobendan) chewable tablets and VETMEDIN solution (pimobendan oral solution) can delay the onset of congestive heart failure (CHF) in dogs
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Subscribe To Our Newsletter & Stay Updated
